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ORIGINAL ARTICLE
Receptor-specific TRAIL as a means to achieve targeted elimination of activated
hepatic stellate cells
Mohammad Arabpoura,b, Robbert H. Coolb, Klaas Nico Faberc, Wim J. Quaxb and Hidde J. Haismab
aMivac Development, Arvid Wallgrens backe 20, Gothenburg, Sweden; bDepartment of Chemical and Pharmaceutical Biology, University of
Groningen, Groningen, the Netherlands; cDepartment of Gastrointestinal and Liver Diseases, University Medical Center Groningen, Groningen,
the Netherlands
ABSTRACT
Activated hepatic stellate cells (HSCs) are known to play a central role in liver fibrosis and their elimination
is a crucial step toward the resolution and reversion of liver fibrosis. Tumor necrosis factor-related apop-
tosis-inducing ligand (TRAIL) is a molecule that may contribute to the apoptotic removal of activated HSC
through binding to its dedicated receptors. In the present study, we investigated the potential application
of recombinant receptor-specific TRAIL proteins in the efficient elimination of activated HSCs. Our finding
revealed differential contribution of TRAIL receptors among HSCs populations with activated hepatic stel-
late cells expresses more TRAIL receptors DR5. In vitro treatment of activated HSCs with DR5-specific or
wild-type TRAIL variants induced a significant reduction in viability and extracellular matrix production,
whereas no significant decrease in viability was associated with the treatment of cells by DR4-specific
TRAIL. Our analysis indicate the successful application of the DR5 receptor-specific TRAIL variant in the tar-
geted elimination of activated HSCs via interference with collagen production and simultaneous induction
of apoptosis via activation of the caspase pathway. DR5 receptor-specific TRAIL may thus represent a new
therapeutic compound for the treatment of liver fibrosis.
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Following chronic injury, the liver develops to a pathologic state
regarded as fibrosis. The key factor in the liver fibrosis process is a
cell type called the hepatic stellate cell (HSC). Quiescent HSCs are
dedicated to retinoid storage, yet through an activation process
due to injury, they proliferate and transform to a myofibroblastic
phenotype. In this form, activated HSCs start secretion of extracel-
lular matrix proteins mainly collagen I and III that accumulate over
time and impair the functional structure of the liver [1]. During
activation, HSC become more susceptible to apoptotic cell death
by apoptotic factors, including tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL). TNFa, FasL and TRAIL are
among the most studied factors in the TNF family members that
employed by a number of immune cells, specially natural killer
cells (NK) and cytotoxic lymphocyte (CTL), to induce controlled
apoptosis in tumor cells or infected cells [2]. Whereas TRAIL,
CD59L and TNFa may have a proliferative effect on HSCs in certain
conditions [3–5] and could cause massive hemorrhagic necrosis of
various tissues, including the liver [6]. Thus, TRAIL is the most
promising apoptotic ligand to eliminate activated HSCs. There are
two death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) that are
responsible for the induction of apoptosis upon binding to TRAIL,
yet TRAIL also can bind to the anti-apoptotic decoy receptors
DcR1 (TRAIL-R3), DcR2 (TRAIL-R4) and osteoprotegerin (OPG). The
application of TRAIL agonists has been suggested as a potential
strategy to eliminate activated HSCs [7,8]. On the other hand, the
ubiquitous expression of TRAIL receptors and the complex role of
apoptosis in inducing inflammation make it difficult to explore
TRAIL ligands for the treatment of liver fibrosis [9,10]. TRAIL recep-
tor-specific agonistic molecules have been introduced both in the
form of TRAIL variants or monoclonal antibodies against specific
TRAIL receptors [11,12]. The dynamics of wild-type (wt) and
mutant TRAIL interactions with TRAIL death receptors have been
well characterized [13]. Receptor-specific agonists may reduce the
decoy receptor-mediated antagonism [14]; hence, by using recep-
tor-specific TRAIL variants, the therapeutic dose is expected to be
lower [13,15]. The application of receptor-specific agonists for DR5
drastically reduced hepatotoxicity [16] that is associated with wild-
type human TRAIL [11,12,16,17]. DR5-specific TRAIL lower toxicity
could be attributed to negligible amount of DR5 on the surface of
healthy hepatic cells in comparison to DR4 [16,17]. In this study,
we investigate the potential application of two receptor-specific
TRAIL variants for targeted elimination of activated HSCs.
Methods
Cell lines and culture
The LX-2 immortalized human HSC line was kindly provided by
Prof. Scott Friedman (Mount Sinai Hospital, New York) and was
cultured in Dulbecco’s minimum essential medium (DMEM) con-
taining 10% fetal bovine serum, (100U/mL) penicillin, 100 g/mL
streptomycin, (50 g/mL) gentamicin and (100 nmol/L) insulin. The
HepG2 human hepatoma cell line (ATCC#HB-8065) and HEK-293
CONTACT Hidde J. Haisma h.j.haisma@rug.nl University of Groningen, Department of Chemical and Pharmaceutical Biology, Antonius Deusinglaan 1,
Groningen, Groningen, 9713 AV, the Netherlands
 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/),
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
JOURNAL OF DRUG TARGETING, 2017
VOL. 25, NO. 4, 360–369
http://dx.doi.org/10.1080/1061186X.2016.1262867
human embryonic kidney cell line (ATCC#CRL-1573) were cultured
in DMEM containing 10% fetal bovine serum. Cells were cultured
in a humidified atmosphere containing 5% CO2 at 37 C.
Primary hepatic cells and animals
Specified pathogen-free male Wistar rats were purchased from
Harlan (Zeist, the Netherlands). They were housed under standard
laboratory conditions and had free access to standard laboratory
chow and water. Each experiment was performed following the
guidelines of the local committee for care and use of laboratory
animals. For isolation and culture of rat hepatocytes and HSCs pri-
mary rat hepatocytes [18] and HSCs [19] were isolated and cul-
tured as described previously. Hepatocyte viability and purity were
always more than 90% as judged by Trypan blue exclusion.
Cells were cultured in a humidified atmosphere containing 5%
CO2 at 37 C.
Antibodies and TRAIL variants
The following antibodies (Ab) were used: anti-TRAIL monoclonal
Ab anti-Human CD253 (TRAIL) (eBioscience Affymetrics Co); mouse
anti-human EGFR IgG Ab; mouse anti-human a-smooth muscle
actin (a-SMA) IgG Ab; goat anti-human collagen I IgG Ab; anti-ß
actin mouse IgG (Sigma-Aldrich, St. Louis, MO). Receptor-specific
TRAIL proteins DHER and 4C7 were produced and purified from
prokaryotic expression systems as previously described [13,15]. For
the apoptosis assay, aAnnexin V-FITC (IQ products, IQP-120F) and
mouse IgG2b-FITC (IQ products, IQP-193F) was used. DR4-specific,
DR5-specific and wild-type TRAIL antibodies were used as previ-
ously described [13].
In vitro evaluation of receptor-specific TRAILs for inducing
apoptosis in HSCs
To activate the LX-2 cells or primary rat HSCs, cells (1000 cells/
well) were seeded and incubated in 96-well, flat-bottomed
uncoated plastic plates in DMEM, Glutamax (Invitrogen) media
with 10% FBS for up to 7 days as previously described [7]. HSCs
were exposed for 48 h to various concentrations of WT TRAIL or
receptor-specific TRAIL variants DHER or 4C7, diluted in DMEM
medium. Primary hepatocytes were seeded at a concentration of
(8000 cells/well) in 96-well, flat-bottomed uncoated plastic plates
overnight before treatment with receptor-specific TRAILs for 48 h.
The effect of different proteins and agents on cell viability were
assessed using MTS (3–(4, 5-dimethylthiazol-2-yl)-5–(3-carboxyme-
thoxyphenyl)-2–(4-sulfophenyl)-2H-tetrazolium), in the presence of
phenazine methosulfate (PMS)) according to the manufacturers
protocol (Sigma) in triplicate. Cell only controls received DMEM
1% FBS.
Immunohistochemistry and western blotting
For SDS-PAGE and western blotting, LX-2 cells were cultured to
50% confluency. At the indicated time points, TRAIL proteins were
added at concentrations ranging from 10 to (100 ng/ml) in DMEM.
For control cells, DMEM was added. After 48 h, the supernatants
were removed and the cells were washed with PBS. The cell pel-
lets were separated on 12.5% SDS-polyacrylamide gels as previ-
ously described [8]. For western blot analysis with Abs against
collagen I, a-SMA and b-actin, gels were blotted on blotting mem-
brane as previously described [8], followed by incubation for 2 h
at room temperature with either an Ab against human collagen I
(1:1000), a-SMA (1:1000) or b-actin (1:5000) in PBS with 1% BSA
and 0.05% Tween-20. After washing, the membrane was incubated
for one hour with the second Ab (horseradish peroxidase (HRP)
conjugated rabbit anti-mouse IgG,; Dako, Denmark) for b-actin and
a-SMA or mouse anti-goat IgG-HRP (Dako, Denmark) in the case of
collagen I, all diluted 1:1000 in the buffer mentioned earlier.
The membrane was then washed four times for 15min in the
washing solution as above. The blot was developed using an
AEC staining solution system (Sigma) according to the man-
ufacturer’s instructions. For immunohistochemistry of cultured
activated LX-2 cells, first LX-2 cells were cultured on uncoated
plastic in 96-well plates with 1% FCS in DMEM for 7 days and
incubated with different concentrations of TRAIL. After 24 h, the
medium was removed and the cells were washed three times
with PBS, fixed with absolute methanol (Sigma) at 20 C for
20min, air-dried for 30min and re-hydrated with PBS for 5min.
Next, the cells were incubated with either anticollagen I (1:75),
anti-a-SMA (1:600) in PBS or 1:10,000 Hoechst 33342. Finally,
the cells were washed with PBS 3 times and incubated with the
second Ab (rabbit anti-mouse IgG-HRP; Dako, Denmark) for
a-SMA and (mouse-anti-goat IgG-HRP; Dako, Denmark) for colla-
gen I all diluted 1:100 in PBS. The integrated density of intracel-
lular insoluble collagen or a-SMA was then calculated through
analysis of five separate pictures from triplicate experiment for
each treatment. All acquisition parameters were kept constant
for samples and respective controls. Images were imported into
Image J 1.48 software. For each wavelength, back ground fluor-
escence has been subtracted from the selected region of inter-
est. The integrated cell density was then calculated and
normalized for the total number of cells for all pictures.
Profiling TRAIL receptor expression on HSCs
Flow cytometer analysis of TRAIL receptors was performed as fol-
lows. HSCs were detached using 0.05% Trypsin-EDTA in PBS,
washed with ice-cold PBS, and diluted to a concentration of
2106 cells/mL using cold PBS. Aliquots of 100 lL (2 105 cells)
were centrifuged at 14,000 rpm for 5min at 4 C, the supernatant
was discarded, and the cells were separately suspended in 100 lL
of rabbit anti-DR4 (10 lg/mL), rabbit anti-DR5 (10lg/mL), rabbit
anti-DcR1 (10lg/mL) or rabbit anti-DcR2 (10lg/mL) antibodies for
TRAIL DR5 and incubated for 45min at 4 C. The cells were then
washed twice with PBS and were incubated for an additional
45min with 1:100 diluted anti-rabbit PE-conjugated secondary
antibody under cold and dark conditions. After two final washings,
cells were suspended in 300 lL PBS (containing 1%BSA). Unlabeled
cells and cells labeled with secondary antibody alone served as
negative controls. The mean values of fluorescence intensity of
10,000 cells were determined by flow cytometry analysis
(Calibur 1).
For the analysis of TRAIL receptor distribution in activated HSC
side populations (SP), LX-2 cells cultured on plastic plates for
7 days in DMEM containing 10% FBS were detached by trypsiniza-
tion for 3min. The number of viable cells was estimated by
Trypan blue staining. Cells were collected by centrifugation and
washed with 5mL of PBS. To detect the SP, LX-2 cells (1 106)
were incubated with Hoechst 33342 (5mg/mL) in DMEM/10% FBS
for 90min at 37 C with vortexing every 15min. Cells were then
stained with specific TRAIL receptor antibodies as explained above.
As previously described [20] to discriminate between SP and non-
SP cells, cells were incubated with the Hoechst dye in the pres-
ence or absence of verapamil (50mM). At the end of the incuba-
tion period, 1mg/mL propidium iodide (PI; Sigma) was added to
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identify dead cells before analysis by flow cytometry for Blue
450 nm (blue Hoechst) and 675 (red Hoechst) laser using the BD
LSR II Flow Cytometer [20]. Gated SP cells were analyzed for
expression of different TRAIL receptors. All FACS data analyzed
with FlowJo VX software.
RNA isolation and real-time RT-PCR analysis
Total RNA from cultured LX-2 cells was isolated using the SV total
RNA isolation system (Promega Z3100) (all tests carried out in trip-
licate). The amount of RNA was measured by NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE) and
analyzed qualitatively by gel electrophoresis. Subsequently, syn-
thesis of first-strand cDNA from total RNA was performed with
Revers Transcription system (Promega A3500) in a volume of
(20lL) containing (250 ng) of oligo dT (Promega, Madison, WI).
The obtained cDNA was diluted with Millipore water (Millipore
Corporation, Billerica, MA) to a concentration of (10 ng/lL), and
(1lL) was applied for each PCR. The a-SMA primer was ordered as
Assays-by-Design (Applied Biosystems, Foster City, CA) (4331348/
assay name ACT-R-ACT2). GAPDH was used as a housekeeping
gene (Applied Biosystems, Foster City, CA). DR5- and DR4-specific
receptors primers were used as previously described [7]. The PCR
was carried out in TaqMan PCR Master Mix (Applied Biosystems,
Foster City, CA) with a final concentration of (200 nM) GAPDH pri-
mers and (250 nM) for the primers of the other genes studied. The
amplification reaction was performed in an ABI PRISM 7900HT
sequence detector (Applied Biosystems) with the following cycling
conditions: 2min at 50 C, 10min at 95 C, and 40 two-step cycles
of 15 s at 95 C and 60 s at 60 C. For each sample, the real-time
PCR was performed in triplicate, and the averages of the obtained
threshold cycle (Ct) values were processed for further calculations
according to the comparative Ct method described in the ABI
manual (http://www.appliedbiosystems.com). In brief, gene expres-
sion levels were normalized to the expression of the housekeeping
gene GAPDH, giving the DCt value. The average value of DCt
obtained from day 0 culture LX-2 was subtracted from the average
of the DCt value of each sample, yielding the DDCt value. Finally,
the gene expression level was calculated as 2–DDCt, giving the final
value that is normalized to the housekeeping gene and relative to
the control sample values of the studied a-SMA gene.
Total soluble collagen assay
The Sircol assay (Biocolor, UK) was used for measuring soluble col-
lagen in culture supernatants. One ml of Sircol dye reagent and
(150 lL) of sample were mixed and incubated for 30min at room
temperature. Collagen–dye complexes were centrifuged for 10min
at 14,000 rpm, washed with 1mL of ethanol and dissolved in 1mL
of (0.5 M) NaOH. The absorbance was measured at 540 nm. The
assay was performed in triplicate, and the mean of data was calcu-
lated for each sample. For caspase and apoptosis assay, caspase
3/7 activities were assayed using the Apo-ONETM Homogeneous
Caspase-3/7 Assay kit (Promega). Briefly, 1 104 HSCs treated with
(100 ng/mL) of the different TRAIL variants or DMEM medium (con-
trol). Cells were transferred into a 96-well plate and (100 lL) of
homogeneous caspase-3/7 reagent was added. The plate was cov-
ered with a plate sealer. After incubation for 2 h, fluorescence of
each well was measured at an excitation wavelength of 485 nm
and an emission wavelength of 530 nm. The measurements are
reported in relative fluorescence units (RFU).
For the evaluation of apoptosis, LX-2 cells were treated with
TRAIL variants as described earlier and harvested at the indicated
time points. Briefly, cells were washed with calcium buffer
((0.15 M) NaCl, (11.7mM) HEPES and (23mM) CaCl2) buffer and re-
suspended in 1/10 dilution of antiannexin V in 60 lL of calcium
buffer. Cells were incubated for 30min at 4 C, washed in calcium
buffer and resuspended in calcium buffer supplemented with
0.5 lg/ml propidium iodate. Finally, fluorescence-activated cell
sorting (FACS) was performed using the BD LSR II Flow Cytometer.
Gated cells were analyzed for apoptotic signaling of annexin V.
All FACS data were analyzed with FlowJo VX software.
Statistical analysis
All experiments were performed in triplicate and averages were
used to calculate for significance between different treatments.
The significance of the difference in TRAIL receptors expression
was analyzed by the Student’s t-test on three separate experi-
ments. p values<.05 were considered to be significant.
Comparisons between different primary cells and or cell lines
treated with TRAIL variants were calculated by using a nonpara-
metric oneway analysis of variance (ANOVA) with Sidak’s multiple
comparison tests with a single pooled variance (p< .05) using
GraphPad Prism version 5.0 for Windows (GraphPad Software, La
Jolla, CA).
Results
TRAIL receptors expression increases during progressive
activation of LX-2 cells in cell culture
LX-2 cells were activated by culturing the cells for 9 days on poly-
ethylene plastic plates This model of progressive activation in cul-
ture has been established for LX-2 cells for the in vitro study of
liver fibrosis [7,8]. Activation of LX-2 cells confirmed by the pheno-
typic transition and increase in a-SMA production. LX-2 cells were
harvested and screened for signs of activation via mRNA expres-
sion of a-SMA, an indicative marker of activation, during different
time points. An increase of fivefold in mRNA and protein expres-
sion of a-SMA was associated with progressive activation
(Figure 1(A)). This model was further used to evaluate the effect of
different TRAIL variants on activated HSCs. We assessed the
expression of the different TRAIL receptors using both real-time
PCR and FACS analysis. Real-time analysis showed that there was
an increased DR4 and DR5 receptor mRNA expression in accord-
ance with the observed activation profile for a-SMA expression in
activated HSCs. The increase in mRNA expression was 100-times
more for the DR4 receptor compared to the DR5 receptor
(Figure 1(B)). Flow cytometry analysis showed that there was a
100% and 10% shift in mean fluorescent intensity of DR4 and DR5,
respectively. However, the level of DR5 expression in comparison
to DR4 was 10-fold higher, which could indicate that DR5 may
play a more important role in TRAIL-mediated apoptosis of HSCs
(Figure 1(C)). The expression of both DcR1 and DcR2 seem to be
absent on LX2 cells and only detectable at low levels in activated
LX2 cells.
DR5-specific TRAIL decreases extra cellular matrix (ECM)
production by activated HSC
One of the characteristic of activated HSCs is the increased expres-
sion of fibrotic markers such as aSMA and collagen I. It has been
previously been shown that TRAIL and TRAIL derivatives could
reduce the expression of ECM produced by activated HSCs.
This has been clearly demonstrated in previous studies. In short,
TRAIL-induced heat-shock factor 1 (HSF1) phosphorylation and
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inactivation, consequently leading to the suppression of heat-shock
protein 47 (Hsp47)-dependent collagen production in activated
human HSCs. Hsp47 is associated with chaperonin folding of pre-
collagen structure into mature soluble collagen form that will be
secreted out of cells. Thus, inhibiting the production of Hsp47
through HSF1 would result in sedimentation of insoluble collagen
in the cells [8,21]. To evaluate the potential effect of receptor-spe-
cific TRAIL on collagen I expression, LX-2 cells were cultured on a
plastic surface for 7 days and different amounts of receptor-specific
or wt TRAIL were added to cell cultures. After 48 h, cells were ana-
lyzed for collagen production using the Sircol assay and western
blotting. Both DR5 and wt TRAIL caused a substantial decrease
(80%) in collagen production, even at very low dose (10 ng/mL),
whereas DR4-specific TRAIL was only capable of a similar effect at a
high dose (Figure 2(A)). It has been reported that the expression of
collagen correlates closely with the expression of collagen-specific
molecular chaperone Hsp47 in activated HSCs. Therefore, we next
investigated the expression of HSP47 in LX-2 cells treated with
increasing amounts of TRAIL variants. The results suggest that a
decrease in collagen production was associated with down regula-
tion of HSP47 in TRAIL-treated cells. Furthermore, DR5 receptor-spe-
cific TRAIL showed a greater capability in reducing HSP47
expression at lower concentration (Figure 2(B,C)). However, the
reduction of collagen was significantly higher in DR5 receptor-spe-
cific TRAIL compared to the DR4 receptor-specific TRAIL. Finally,
staining of TRAIL treated LX-2 cells with anticollagen I and anti-
a-SMA revealed increase in intracellular insoluble collagen is associ-
ated with decrease in a-SMA. Moreover, the aggregation of insol-
uble collagen and reduction in the expression of a-SMA were more
pronounced in cells treated with DR5-specific TRAIL, thus indicating
with DR5 specific TRAIL seems to interfere more efficiently with col-
lagen folding mechanism (Figure 3).
Different receptor-specific TRAILs have different potential to
eliminate activated HSCs
To evaluate the potential cytotoxic effect of receptor-specific
TRAIL, different amounts from each receptor-specific or wt TRAIL
Figure 1. LX2 cells activation and TRAIL receptor expression profile. Alpha SMA mRNA and protein expression increase as a sign of activation due to progressive culture
of LX2 cells in vitro during 9 days(A); (B) mRNA expression profile of TRAIL receptors 1 and 2 in activated LX2 cells by real time PCR; (C) Flow cytometry analysis of
TRAIL receptors in LX2 cells. An increase in the expression of surface receptors is associated with the activation of HSCs during culture induced activation.
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protein were added to activated or quiescent LX-2 HSCs and the
viability of cells was determined 72 h later by the MTS assay
(Figure 4). Activation of LX-2 cells confirmed by the phenotypic
transition and increase in a-SMA production showed a substantial
decrease in viability by increasing doses of TRAIL. A comparison
between the different TRAIL variants showed that DR5-specific
TRAIL was more potent in reducing viability (60%), whereas treat-
ment with DR4-specific TRAIL did affect the viability of activated
HSC, only in the presence of high concentrations of TRAIL.
Treatment of quiescent LX-2 with different types of TRAIL, on the
other hand, did not significantly affect the viability even at the
highest concentrations (1lg/ml). Finally, to examine the specificity
of the different TRAIL variants to HSCs, the hepatic parenchymal
cancer cell line HepG2 was treated with increasing concentrations
of DR4, DR5 and wt TRAIL. Whereas no detectable difference in
viability of HepG2 cells was observed after application of wt TRAIL,
Figure 2. Interfering in LX2 cells collagen production by receptor-specific TRAIL variants. Representative sircol assay for collagen (A) and protein production (B) in LX2
cells treated with sublethal dose of different receptor specific variants and wt TRAIL; (C) HSP47 mRNA expression and (D) protein production in LX2 cells treated with
two different concentration of TRAIL proteins.
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a decrease in viability was observed with the DR4 or the DR5 spe-
cific TRAIL proteins (Figure 5(C)). These findings confirm the select-
ivity of the wt TRAIL protein toward activated HSC. The inhibition
of the viability in primary activated rat HSC was lower than in LX-
2 cells and was only found at high doses of DR5-specific TRAIL
(1lg/mL), which showed a 20% reduction in viability (Figure 5(E)).
No significant reduction in viability was observed after treatment
with the different TRAIL variants of quiescent rat HSCs or rat hepa-
tocytes. We next evaluated the contribution of the different TRAIL
receptor variants with respect to induce apoptosis using the cas-
pase 3/7 activity assay. The measurement of caspase activity in
HSCs treated with TRAIL showed a higher caspase activity for DR5-
and WT-treated cells versus DR4-treated LX-2 cells. Data obtained
were normalized to the untreated cell line (Figure 5(A)). To further
Figure 3. Imunohistochemistry staining of LX2 cells treated with TRAIl proteins showed decrease in the number of aSMA-positive cells and increase in intracellular-
insoluble collagen deposition. Activated LX2 cells treated with 50 ng/mL of different TRAIL proteins or DMEM (control) for 48 h and stained for collagen or a-SMA and
Hoechst nuclear staining (A); integrated density of intracellular-insoluble collagen and a-SMA in LX2 cells affected by different TRAIL or DMEM (control) (B).
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investigate the apoptosis-inducing activities of the different TRAIL
variants, LX-2 cells were incubated with PBS or the TRAIL variants
proteins for 48 h. Consistent with the cell viability results, only WT
and DR5-specific TRAIL-induced robust apoptosis of LX-2 cells,
whereas DR4-specific TRAIL was less effective as measured by
Annexin V FACS analysis (Figure 5(B)).
Discussion
Persistent liver injury lead to enhanced ECM production and accu-
mulation, a condition referred to as liver fibrosis. HSCs have a cen-
tral role in this process, it has been shown that activated HSCs
significantly amplify the hepatic response to liver injury, hence
depleting fibrotic livers from activated HSCs may ameliorate the
fibrotic condition [22]. TRAIL-induced apoptosis was successfully
used to eliminate activated HSC [7]. In order to increase the speci-
ficity and to be able to lower the effective dose of TRAIL, we eval-
uated the different properties of receptor-specific TRAILs as a
selective treatment for the elimination of activated HSCs to
improve the remedy from liver fibrosis. To uncover the dynamics
of TRAIL receptor expression during time-dependent HSC
activation, the expression pattern of different TRAIL receptors on
the surface of quiescent and activated HSCs was evaluated. Our
findings cast light on the differential contribution of TRAIL recep-
tors in HSCs. An increase in the level of TRAIL DR5 and DR4 recep-
tors was observed both in mRNA and protein expression upon
activation of HSCs. Despite the increase in TRAIl-DR4 receptor
expression during activation, the net expression remained signifi-
cantly lower than that of the TRAIl-DR5 receptor. An increase in
the expression of TRAIL receptors was concomitant with an
increase in expression of TRAIL decoy receptors, especially DcR2.
As part of our study, we demonstrated that the DR5 receptor was
the single most dominant receptor on HSCs in comparison with
the HSC side population, whereas decoy receptor DcR2, was pre-
dominantly expressed on the surface of HSC side population. This
finding is particularly important since It has been proven that
HSCs may directly undergo mesenchymal-to-epithelial transition to
transdifferentiate into liver progenitors [23,24] or indirectly aug-
ment regeneration of hepatic cells by its produced cytokines
[25,26]. The exact mechanisms by which HSCs may help mediate
liver regeneration and the relative importance of different sub-
types of HSCs remain to be determined. However, crucial regen-
erative role of the SP in multiple organs imply the possibility for
Figure 4. TRAIL efficiency in eliminating activated HSCs viability differs depends on TRAIL variants. MTS viability assay for quiescent LX2 cells (A); activated LX2 cells
(B); parenchymal hepatic cells (Hep-G2) (C); activated rat primary HSCs (D); quiescent rat primary HSCs (E); parenchymal rat primary hepatic cells (F).
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this population to have similar role in liver regeneration. Thus,
next to the higher expression of TRAIL receptors on activated
HSCs the selectivity of TRAIL variants could be partially explained
by the higher expression of the decoy receptors in SP HSCs than
in rest of population. Our findings therefore, show the protective
role of TRAIL decoy receptor 2 in HSCs SP.
To further evaluate the application of different receptor-specific
TRAIL agonists in eliminating activated HSCs, we explored the
functional capacity of receptor-specific TRAIL variants [13,15,26] in
inducing apoptosis and reducing ECM production in HSCs. ECM-
producing cells, such as HSC, are highly responsive to a series of
factors, such as EGF, PDGF and TGF-b, that are released from dam-
aged liver parenchyma during the fibrotic process. Affected HSCs
start producing excessive amount of ECM. The production of ECM,
especially collagen I, could in return accelerate HSC proliferation
and fibrosis [27,28]. Addressing this phenomenon, we evaluated
the capability of different TRAIL variants in blocking ECM produc-
tion by HSCs. All TRAIL variants suppressed the production of sol-
uble collagen by activated HSCs with DR5 receptor-specific and wt
TRAIL being the most potent molecules. This observation was
accompanied by downregulation of the pro-collagen specific
molecular chaperone Hsp47 and aggregation of insoluble collagen
in TRAIL-treated cells. These findings cast light on the supporting
mechanism of receptor-specific TRAIL mediated collagen regula-
tion through interfering with the natural folding and secretion
process of pre-collagen in activated HSCs. A direct relation has
already been established between fibrogenesis and the number of
a-SMA positive cells [29]. Since the increase in accumulation of
insoluble collagens in our study was associated with a reduced
number of a-SMA positive cells, it may be speculated that the
decreased expression of ECM proteins is caused by the reduction
in HSC activation and proliferation. The exact mechanism for this
phenomenon yet to be defined, but it has been shown that TRAIL
could inhibit cellular growth in the absence of cell death induction
due to cyclin dependent cell cycle arrest in S-G2/M phase [30–32].
Hence, inhibition of HSCs activation and proliferation by TRAIL
could directly reduce secretion of ECM including collagen I.
An alternative mechanism for reduced activation of TRAIL-affected
HSCs could be attributed to role of pericellular collagen on HSCs
proliferation. There is accumulating evidence that HSC biology is
tightly regulated by their peripheral ECM environment. It has been
shown collagen I, the major component of fibrosis, enhances the
proliferation of HSC in vitro via different mechanisms, that is, inter-
acting with type-2 discoidin domain receptor [33,34]. Thus, TRAIL
property for in vitro eliminating ECM accumulation through inter-
fering with pro-collagen folding and secretion could eliminate
HSCs proliferation and promote reversion of the fibrotic pheno-
type of activated HSCs [35].
Our findings revealed a substantial decrease in LX-2 HSC viabil-
ity achieved through exposure to DR5-specific and wt TRAIL,
whereas DR4-specific TRAIL showed only a marginal effect on LX-2
cell viability. This finding is in concordance with findings regarding
the functional role of different TRAIL variants in inducing apop-
tosis as measured by increase in caspase 3/7 and Annexin V [7].
Selectivity of TRAIL variants is an important issue since apoptosis
in itself could have a dual function in ameliorating or deteriorating
fibrosis progression. Here, we showed that the effects of receptor
specific TRAIL variants are limited to the HSCs rather than the
Figure 5. Comparison of caspase 3/7–8 enzyme activity and Annexin V in activated HSCs treated with different TRAIL variants. An increase in the amount of caspase-3/
7–8 activity in LX2 cells (A); treated with TRAIL variants is concurrent with increase in apoptosis marker Annexin V in FACS analysis with a significant difference
between DR5- and DR4-specific apoptosis induction (p< .05) (B).
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hepatocytes. The observed sensitivity of HepG2 cells towards
receptor-specific TRAIL could be partially explained through its
over expression of pro-apoptotic TRAIL receptors and DcR2 in hep-
atocellular carcinoma cell line [36]. Since fibrosis is considered
rather a long term and persistent problem, a durable and efficient
approach need to be pursued. Our current strategy to dissect the
functional properties of different TRAIL variants is particularly
beneficial since TRAIL shows a very short half-life (6 h) in vivo and
thus needs high dosages and frequencies of administration for
clinical benefit. We speculate that an advantage of treatment with
receptor-specific TRAIL variants is the specific targeting of acti-
vated HSCs and lowering required dosage for having the same
effect. Moreover, given that TRAIL variants carry both separate
functions for simultaneously inducing apoptosis through TRAIL
receptors and reducing ECM production via blocking relevant sig-
naling pathways in HSCs, it appears to be an ideal combination
for eliminating fibrotic process. Hence, a loss of viability in TRAIL-
treated activated HSCs could be followed by a lower proliferation
and reversion to quiescent phenotype of remaining activated HSC.
This is particularly important for sustaining the effect of TRAIL.
Furthermore, TRAIL variants may be applied as genetic therapy
[37] resulting in highly effective long-term in vivo elimination of
activated HSCs and reduction of ECM production. In this regard,
our study is the first to show a significant antifibrotic effect of dif-
ferent receptor-specific TRAIL variants, which warrants further in
vivo studies (Figure 6).
TRAIL is a molecule that have been long known for its proper-
ties in cancer therapy. Due to its natural role in mediating reso-
lution of liver fibrosis TRAIL has been recently addressed as a
potential attractive candidate for treatment of liver fibrosis.
Despite the extensive work carried out to elucidate the molecular
mechanism of TRAIL and its dedicated receptors in cancer cells,
less is known about the role of TRAIL receptors in elimination of
hepatic stellate cells. In this study, we investigated receptor
specific TRAIL or wild-type TRAIL for their role in the elimination
of activated HSCs as the major player in liver fibrosis process. Our
results indicate more than one receptor is responsible for recogni-
tion and signal transduction of TRAIL into activated HSCs. DR5
receptors were demonstrated to be the most frequent receptor on
the surface of activated hepatic stellate cells. Consequently, we
demonstrate DR5-specific TRAIL is highly favorable to eliminate
this type of cell. Decrease in viability due to exposure with differ-
ent TRAIL variants associate with an increase in caspase activity
and apoptosis induction in activated hepatic stellate cells. Also,
the application of sub toxic dosage of different TRAIL variants
result in pronounced reduction in extra cellular matrix production
correlate with their inhibitory effect on production of pro-collagen
specific folding molecule chaperonin HSP-47. The overall finding
from this study shed light on the involvement of different TRAIL
receptors in eliminating activated HSCs that could pave the way
for its future utility of receptor specific TRAIL-based antifibrosis
therapy.
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